Literature DB >> 1431974

Aseptic meningitis associated with high dose intravenous immunoglobulin therapy.

M Casteels-Van Daele, L Wijndaele, P Brock, M Kruger, P Gillis.   

Abstract

Entities:  

Mesh:

Year:  1992        PMID: 1431974      PMCID: PMC1015216          DOI: 10.1136/jnnp.55.10.980-b

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  4 in total

1.  Aseptic meningitis associated with high dose intravenous immunoglobulin therapy.

Authors:  J D Watson; J Gibson; D E Joshua; H Kronenberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-03       Impact factor: 10.154

2.  Intravenous immune globulin and acute aseptic meningitis.

Authors:  M Casteels-Van Daele; L Wijndaele; K Hanninck; P Gillis
Journal:  N Engl J Med       Date:  1990-08-30       Impact factor: 91.245

3.  Administration of immune globulin associated with aseptic meningitis.

Authors:  E Kato; S Shindo; Y Eto; N Hashimoto; M Yamamoto; Y Sakata; Y Hiyoshi
Journal:  JAMA       Date:  1988-06-10       Impact factor: 56.272

4.  Spinal subarachnoid hematoma complicating lumbar puncture: diagnosis and management.

Authors:  E W Scott; C R Cazenave; C Virapongse
Journal:  Neurosurgery       Date:  1989-08       Impact factor: 4.654

  4 in total
  3 in total

Review 1.  Drug-induced aseptic meningitis: diagnosis and management.

Authors:  S Jolles; W A Sewell; C Leighton
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

Review 2.  Intravenous immunoglobulin for Guillain-Barré syndrome.

Authors:  Richard A C Hughes; Anthony V Swan; Pieter A van Doorn
Journal:  Cochrane Database Syst Rev       Date:  2014-09-19

Review 3.  Intravenous Immunoglobulin-Induced Aseptic Meningitis-A Narrative Review of the Diagnostic Process, Pathogenesis, Preventative Measures and Treatment.

Authors:  Anna Kretowska-Grunwald; Maryna Krawczuk-Rybak; Malgorzata Sawicka-Zukowska
Journal:  J Clin Med       Date:  2022-06-21       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.